Lilly rallies on European oncology nod and Medicare GLP-1 access expansion
Eli Lilly shares climbed sharply after the European Medicines Agency’s CHMP issued a favorable opinion for Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia and the company published Medicare GLP-1 Bridge Program guidance that would allow eligible Medicare Part D patients access to Zepbound and Foundayo for $50 per month. An analyst price-ta…